LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Data from the Centers for Disease Control and Prevention showed an increase in three respiratory viruses—COVID-19, flu and RSV—and the gastrointestinal disease norovirus. Emergency department ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

Cases of RSV across the country are considered "very high," as rates of other acute respiratory illnesses are also high, the CDC reported Monday. Here's what to know about RSV. Iowa currently is ...

So far there have been 32 flu-related deaths in Pennsylvania for the 2024-25 season. For RSV, 4,103 cases were reported last week, up 14% from the previous week. In the Lehigh Valley, cases of ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.